Esiflo 500 Transcaps is a combination medication containing Salmeterol 50mcg and Fluticasone Propionate 500mcg, indicated for the maintenance treatment of asthma and chronic obstructive pulmonary disease (COPD). Salmeterol, a long-acting beta2-adrenergic receptor agonist, provides bronchodilation by relaxing airway smooth muscle, thereby improving airflow and reducing symptoms such as wheezing and shortness of breath. Fluticasone Propionate, a potent corticosteroid, exerts anti-inflammatory effects by inhibiting multiple inflammatory cells and mediators, reducing airway inflammation and hyperresponsiveness. The synergistic action of these agents helps to control persistent respiratory symptoms, prevent exacerbations, and improve lung function. Esiflo 500 Transcaps is administered via inhalation, allowing targeted delivery to the lungs with minimal systemic exposure. It is intended for regular use and not for relief of acute bronchospasm. Patients should be monitored for potential side effects including oral candidiasis, dysphonia, and paradoxical bronchospasm. Use with caution in patients with cardiovascular disorders or hypersensitivity to any component. Esiflo 500 Transcaps should be used under medical supervision with adherence to prescribed dosage to optimize therapeutic outcomes and minimize risks.